Clinical trials: DME
Diabetic Macular Edema
Study of Two Multiple Intravitreal Doses of BAT5906 for Safety and Efficacy in Patients With Diabetic Macular Edema
This study is a multi-center, open, multiple-dose phase Ib/IIa clinical study evaluating the efficacy and safety of BAT5906 injection in patients with diabetic macular edema.
- Trial name
- NCT04772105
- Testing
- 2.5mg of BAT5906, 4.0mg of BAT5906
- Where
- 19 sites in China
- Volunteers
- 60 people
- Sponsor
- Bio-Thera Solutions
Diabetic Macular Edema, DME
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
- Conditions
- Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- Trial name
- DME (NCT07449923)
- Testing
- EYP-1901, Aflibercept (2.0 mg)
- Where
- 70 sites in United States, Brazil and 3 more
- Volunteers
- 240 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Diabetic Macular Edema
A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema
Researchers are looking for a better way to treat people who have diabetic macular edema. Diabetic macular edema (DME) is a diabetes-related eye disorder.
- Trial name
- PHOTONiC (NCT06422507)
- Testing
- 8 mg aflibercept (BAY 86-5321) (High Dose), 2 mg aflibercept (EYLEA, BAY 86-5321)
- Where
- 52 sites in China, Hong Kong
- Volunteers
- 333 people
- Sponsor
- Bayer
Diabetic Macular Edema
Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT
Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT The purpose of this study is to collect data on the NVHO device at up to three sites.
- Trial name
- NCT05745116
- Testing
- Notal Vision Home OCT
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Notal Vision Inc.
Diabetic Macular Oedema
To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus
To demonstrate the comparative effectiveness of 12 months of Lucentis (ranibizumab) in patients with well controlled compared to those with poorly controlled diabetes using an PRN treatment schedule.
- Trial name
- CONTROL (NCT03495765)
- Testing
- Ranibizumab
- Where
- Australia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Marsden Eye Specialists
Diabetic Macular Edema
Treatment of Diabetic Macular Edema With Aflibercept and Micropulse Laser
The goal of this pilot study is to investigate the safety and efficacy of micropulse (MP) macular laser in combination with intravitreal aflibercept for the treatment of centre-involved diabetic macular edema.
- Trial name
- DAM (NCT03143192)
- Testing
- Micropulse Laser
- Where
- 2 sites in Canada
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Keyvan Koushan
Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
- Trial name
- JADE (NCT07484074)
- Testing
- Faricimab, OLN324
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 164 people
- Sponsor
- Ollin Biosciences, Inc.
Diabetic Macular Edema
Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)
This study will evaluate the efficacy and safety of Betamethasone Microsphere (DE-102) for diabetic macular edema.
- Trial name
- NCT01411254
- Testing
- Betamethasone Microsphere (DE-102） Low Dose, Betamethasone Microsphere (DE-102） High Dose
- Where
- Japan
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Diabetic Macular Edema
A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients
This is a clinical study to evaluate the safety, tolerability and initial efficacy of SKG0106 intravitreal injection in diabetic macular edema (DME) patients.
- Trial name
- NCT06237777
- Testing
- SKG0106 intravitreal injection dose level 1, 2 or 3
- Where
- 2 sites in China
- Volunteers
- 3 people
- Sponsor
- Wang Min
Diabetic Retinopathy, Diabetic Macular Edema (DME)
AI Prediction of Treatment Response in DME
Diabetic macular edema (DME) is a leading cause of vision loss among individuals with diabetes mellitus. Although intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard treatment for…
- Trial name
- NCT07707856
- Testing
- Artificial Intelligence-Based Imaging Analysis
- Where
- Egypt
- Volunteers
- 1,284 people
- Sponsor
- Benha University
Diabetic Macular Edema, Retina Vein Occlusion
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
Phase 2a multicenter, open-label, parallel-arm design study to evaluate the safety, tolerability and pharmacodynamics of a single intravitreal injection comparing 2 dose levels of GB-102 on subjects with Diabetic Macular Edema…
- Trial name
- NCT04085341
- Testing
- GB-102
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Graybug Vision
Diabetic Macular Edema
Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema
The investigators hypothesize that a combination treatment with Avastin and Ozurdex will result in a more rapid improvement of visual acuity compared to the use of Avastin alone.
- Trial name
- NCT01309451
- Testing
- Bevacizumab, dexamethasone intravitreal implant
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Diabetic Macular Edema
Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema
The purpose of this study is to assess the safety and tolerability of MP0112 (a novel, potentially long acting VEGF inhibitor) in patients with diabetic retinal edema.
- Trial name
- NCT01042678
- Testing
- MP0112
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Allergan
Diabetic Macular Edema
Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema
This Phase 1 study will evaluate the safety, tolerability and duration of effect of a helical intravitreal triamcinolone implant for the treatment of diabetic macular edema over a three-year period.
- Trial name
- STRIDE (NCT00915837)
- Testing
- triamcinolone acetonide
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- SurModics, Inc.
Diabetic Macular Edema (DME)
A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema…
- Trial name
- BRUNELLO (NCT06571045)
- Testing
- Ranibizumab, Remigromig
- Where
- 183 sites in United States, Argentina and 18 more
- Volunteers
- 984 people
- Sponsor
- EyeBiotech Ltd.
Diabetic Macular Edema
Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)
This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.
- Trial name
- NCT00536692
- Testing
- mecamylamine
- Where
- 3 sites in United States
- Sponsor
- CoMentis
Diabetic Macular Edema
Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema
A multicenter, randomized, double-blind, parallel-controlled phase I trial comparing the safety, pharmacokinetics and efficacy of 9MW0813 and aflibercept (EYLEA®) after a single dose in patients with diabetic macular edema (DME).
- Trial name
- NCT05324592
- Testing
- 9MW0813, Aflibercept
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Diabetic Macular Edema
Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)
To evaluate, specifically within the Canadian medical environment, the efficacy, safety and cost-efficacy of ranibizumab administered either as combination therapy (ranibizumab plus laser photocoagulation), or as monotherapy in…
- Trial name
- RESPOND (NCT01135914)
- Testing
- ranibizumab, Laser
- Where
- 20 sites in Canada
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Macular Edema
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with clinically significant macular edema with center involvement…
- Trial name
- RISE (NCT00473330)
- Testing
- Ranibizumab
- Volunteers
- 377 people
- Sponsor
- Genentech, Inc.
Diabetic Macular Edema
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
The purpose of this study is to generate additional safety and effectiveness data in Indian Diabetic macular edema (DME) patients that more closely resemble the real-world population intended to be treated with Brolucizumab.
- Trial name
- NCT05959304
- Testing
- brolucizumab
- Where
- 8 sites in India
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals